絞り込み

17361

広告

Kras mutations and PU.1 promoter methylation are new pathways in murine radiation-induced AML.

著者 O'Brien G , Cruz-Garcia L , Zyla J , Brown N , Finnon R , Polanska J , Badie C
Carcinogenesis.2019 Oct 24 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (13view , 0users)

Full Text Sources

Miscellaneous

Therapy-related and more specifically radiotherapy associated acute myeloid leukaemia (AML) is a well-recognised potential complication of cytotoxic therapy for the treatment of a primary cancer. The CBA mouse model is used to study radiation leukaemogenesis mechanisms with Sfpi1/PU.1 deletion and point mutation already identified as driving events during AML development. To identify new pathways, we analysed 123 mouse radiation-induced AML (rAML) samples for the presence of mutations previously identified in human AML and found 3 genes to be mutated; Sfpi1 R235 (68%), Flt3-ITD (4%) and Kras G12 (3%), of which G12R was previously unreported. Importantly, a significant decrease in Sfpi1 gene expression is found almost exclusively in rAML samples without a Sfpi1 R235 mutation and is specifically associated with up-regulation of mir-1983 and mir-582-5p. Moreover, this down-regulation of Sfpi1 mRNA is negatively correlated with DNA methylation levels at specific CpG sites upstream of the Sfpi1 transcriptional start site. The down regulation of Sfpi1/PU.1 has also been reported in human AML cases revealing one common pathway of myeloid disruption between mouse and human AML where dysregulation of Sfpi1/PU.1 is a necessary step in AML development.
PMID: 31646336 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード